SCHEMBL13321925

SCHEMBL13321925

CC(=O)NC1[C@@H](O[C@@H]2OC(C(=O)O)[C@@H](O)[C@H](O)C2O)[C@H](OOOOS)C(CO)O[C@@H]1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.44
▸ LGALS8 O00214 1/20 0.44
▸ LGALS4 P56470 1/20 0.44
▸ BDNF P23560 3/20 0.38
▸ PTN P21246 2/20 0.38
▸ MDK P21741 2/20 0.38
▸ CD69 Q07108 1/20 0.36
▸ MAPK1 P28482 2/20 0.35
▸ CHIA Q9BZP6 1/20 0.35
▸ LGALS1 P09382 1/20 0.34
▸ LGALS7; LGALS7B P47929 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ LGALS9 O00182 1/20 0.33
▸ SELL P14151 1/20 0.33
▸ SELP P16109 1/20 0.33
▸ AMY2A P04746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13321932 0.88 MDK (0.51) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL16085016 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL26842303 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL16269844 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL12580124 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL25024651 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL12552832 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL22112013 0.86 LGALS3 (0.48) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL23336378 0.83 MDK (0.53) LGALS3LGALS8LGALS4BDNFPTN
SCHEMBL12009749 0.81 MAPK1 (0.46) LGALS3LGALS8LGALS4BDNFPTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100129331-A1 DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES BIOIBERICA, S.A. (ES) 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129331-A1 DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES IGFBP1, FGF1, IGFBP2 LGALS3 48/4885LGALS8 107/4885LGALS4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback